Last updated: February 21, 2026
What is NDC 51672-1297?
NDC 51672-1297 corresponds to a specific pharmaceutical product. Based on available data, this NDC identifies Erelzi (etanercept), a biosimilar for Enbrel (etanercept), used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Current Market Landscape
Product Overview
- Brand: Erelzi (biosimilar)
- Manufacturer: Sandoz (a Novartis division)
- Therapeutic Class: Tumor necrosis factor (TNF) inhibitors
- Indications: Rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis
Market Penetration
Erelzi entered the US market post-FDA approval in August 2018. Historically, biosimilars like Erelzi have struggled with market penetration due to patent protections, physician familiarity, and payer dynamics.
Competitive Landscape
| Product |
Brand Name |
Manufacturer |
Launch Year |
Market Shares (2022) |
List Price (per 50 mg dose) |
| Enbrel |
Enbrel |
Amgen |
1998 |
~40% |
$2,667 |
| Erelzi |
Erelzi |
Sandoz |
2018 |
~7% |
$1,700 (approximate) |
| Inflectra |
Inflectra |
Celltrion |
2016 |
~8% |
$1,600 |
| Amjevita |
Amjevita |
Amgen |
2016 |
~6% |
$1,600 |
Market share for biosimilars increased from 20% in 2020 to approximately 30% by 2022, indicating gradual acceptance.
Price Trends and Projections
Historical Pricing Dynamics
Initial list prices of biosimilars like Erelzi are 35-40% lower than the originator. Over time, discounts to list prices have increased due to competition.
Forecasted Price Trajectory
| Year |
Expected List Price (per 50 mg dose) |
Notes |
| 2023 |
~$1,700 |
Stabilization; limited additional discounts |
| 2024 |
~$1,600 |
Slight price reductions as more biosimilars enter |
| 2025 |
~$1,550 |
Increased payer negotiations, volume discounts |
| 2026 |
~$1,500 |
Marginal decreases; market saturation limits further discounts |
Key Drivers of Future Pricing
- Market Penetration: Slow uptake limits aggressive price declines.
- Payer Negotiations: Payers push for lower prices, driving discounts.
- Generic Competition: Entry of additional biosimilars will increase price competition.
- Regulatory Changes: Policy shifts may influence drug reimbursement and pricing.
Revenue Projections
Assuming the US market for etanercept biosimilars reaches ~$1.2 billion by 2026, with Erelzi capturing a 15% share, annual revenues would approximate $180 million at current prices. Volume growth is projected to be steady at 3-5% annually.
Market Challenges and Opportunities
Challenges
- Manufacturing complexities of biosimilars delay large-scale production.
- Physician and patient familiarity favors originator.
- Payer resistance drives discounts and formulary exclusion.
- Patent litigations and exclusivity clauses slow biosimilar entry.
Opportunities
- Growing acceptance of biosimilars reduces cost barriers.
- Policy initiatives incentivize biosimilar adoption.
- Competitive pricing can expand market share.
- Developing combination therapies could open new markets.
Key Takeaways
- NDC 51672-1297 (Erelzi) is a biosimilar to Enbrel with modest market share since 2018.
- List prices for etanercept biosimilars have stabilized around $1,500-$1,700 per 50 mg dose through 2023.
- Market penetration remains gradual due to physician preferences and payer negotiations.
- Price declines are expected to be incremental over the next three years.
- Entry of additional biosimilars and policy shifts could drive further price erosion but will also expand market volume.
FAQs
1. When did Erelzi receive FDA approval?
August 2018.
2. How does Erelzi’s price compare to Enbrel?
Erelzi’s list price is approximately 35-40% lower than Enbrel’s, but discounts vary across payers.
3. What factors influence biosimilar adoption?
Physician familiarity, payer policies, patent disputes, and manufacturing capacity.
4. Are biosimilar prices expected to decline further?
Yes, incremental reductions are projected as competition increases and market share expands.
5. What is the outlook for biosimilar market share in autoimmune therapies?
Market share is expected to grow from around 30% in 2022 to approximately 50% by 2026, assuming continued policy support and industry growth.
References
[1] IQVIA. (2022). US Biosimilar Market Data.
[2] FDA. (2018). Erelzi Approval Announcement.
[3] Bloomberg. (2022). Biosimilar Pricing Trends and Market Penetration.
[4] PhRMA. (2023). Biosimilars Year in Review.
[5] EvaluatePharma. (2023). Biopharma Market Forecasts.
